Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake

4 weeks ago 14

Jonathan Ponciano, The Motley Fool

Mon, February 23, 2026 astatine 9:46 AM CST 4 min read

On February 17, 2026, Commodore Capital disclosed successful an SEC filing that it sold retired its full 3,200,000-share presumption successful Viridian Therapeutics (NASDAQ:VRDN), an estimated $69.06 cardinal transaction based connected last-disclosed presumption values.

According to a filing with the Securities and Exchange Commission dated February 17, 2026, Commodore Capital reported selling its full 3,200,000-share involvement successful Viridian Therapeutics. The nett presumption alteration for the 4th was $69.06 million, reflecting the removal of the holding from the portfolio.

The liquidation of Viridian Therapeutics reduced its weighting from 3.4% of 13F AUM successful the anterior 4th to zero aft the filing.
Top holdings aft the filing:
- NASDAQ: RLAY: $143.82 cardinal (9.6% of AUM)
- NASDAQ: ALKS: $99.33 cardinal (6.6% of AUM)
- NASDAQ: TYRA: $88.73 cardinal (5.9% of AUM)
- NASDAQ: XENE: $80.68 cardinal (5.4% of AUM)
- NASDAQ: SYRE: $78.24 cardinal (5.2% of AUM)
As of February 17, 2026, shares of Viridian Therapeutics were priced astatine $28.29, up 75% implicit the anterior twelvemonth and good outperforming the S&P 500.

Metric

Value

Price (as of marketplace adjacent February 17, 2026)	$28.29
Market capitalization	$2.30 billion
Revenue (TTM)	$70.79 million
Net income (TTM)	($301.97 million)

Viridian Therapeutics develops monoclonal antibody therapies, including VRDN-001, VRDN-002, and VRDN-003, chiefly targeting thyroid oculus illness (TED).
The institution generates gross done the improvement and imaginable commercialization of caller biologic drugs, with a absorption connected advancing clinical-stage assets for uncommon and superior diseases.
Primary customers are healthcare providers and patients affected by TED and related conditions, with a absorption connected the biotechnology and specialty pharmaceutical markets.

Viridian Therapeutics, Inc. is simply a clinical-stage biotechnology institution specializing successful the improvement of innovative antibody-based therapies for superior diseases, with a pb absorption connected thyroid oculus disease. The institution leverages expertise successful monoclonal antibody engineering to beforehand its pipeline and code unmet aesculapian needs successful uncommon disorders. With a increasing portfolio and a targeted attack to specialty markets, Viridian aims to found a competitory presumption successful the biotechnology assemblage done differentiated therapeutics and objective progress.

Biotech portfolios are built connected conviction, but they are besides built connected timing. When a manager clears retired a afloat presumption up of large catalysts, it’s surely thing to instrumentality enactment of.

To beryllium fair, Viridian enters 2026 with plentifulness of imaginable catalysts. The FDA accepted veligrotug’s BLA for thyroid oculus illness with a June 30 PDUFA day nether Priority Review, and topline Phase 3 information for subcutaneous elegrobart are owed successful the archetypal fractional of the year. The institution ended October with astir $888 cardinal successful currency and investments and says it expects to money operations done profitability. Plus, shares astatine $28.29 are up astir 75% implicit the past year.

So wherefore would Commodore measurement aside? Within this portfolio, superior remains concentrated successful clinical-stage names specified arsenic Relay astatine astir 10% of assets, Alkermes astatine 7%, and Tyra astatine 6%. But removing a 3.4% value suggests either valuation subject aft a beardown tally oregon a penchant for different pipelines.

Ultimately, the determination looks similar it’s astir hazard calibration. Viridian is present moving into a catalyst-heavy year. Approval and cleanable information could validate the rally. Any stumble would reset expectations quickly.

Read Entire Article